Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $54,600.00 in Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 5,000 shares of the stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $10.92, for a total value of $54,600.00. Following the completion of the sale, the director now directly owns 806,283 shares in the company, valued at approximately $8,804,610.36. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Cyrus Harmon also recently made the following trade(s):

• On Tuesday, April 30th, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $9.51, for a total value of $142,650.00.
• On Thursday, March 28th, Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $10.97, for a total value of $219,400.00.
• On Thursday, February 29th, Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $12.41, for a total value of $310,250.00.

Olema Pharmaceuticals Stock Down 3.5 %

NASDAQ:OLMA opened at $10.85 on Thursday. The stock’s 50 day moving average price is $11.39 and its 200 day moving average price is $12.84. The company has a market capitalization of $606.84 million, a PE ratio of -5.02 and a beta of 2.10. Olema Pharmaceuticals, Inc. has a 52-week low of $5.02 and a 52-week high of $17.79.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings results on Monday, March 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.49). As a group, sell-side analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio purchased a new position in shares of Olema Pharmaceuticals in the 3rd quarter valued at approximately $35,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Olema Pharmaceuticals in the 4th quarter valued at approximately $89,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Olema Pharmaceuticals in the 4th quarter valued at approximately $130,000. SG Americas Securities LLC purchased a new position in shares of Olema Pharmaceuticals in the 3rd quarter valued at approximately $142,000. Finally, Entropy Technologies LP purchased a new position in shares of Olema Pharmaceuticals in the 1st quarter valued at approximately $161,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on OLMA. Citigroup began coverage on Olema Pharmaceuticals in a research report on Tuesday, January 30th. They set a “buy” rating and a $20.00 target price on the stock. The Goldman Sachs Group began coverage on Olema Pharmaceuticals in a research report on Tuesday, April 2nd. They set a “buy” rating and a $24.00 target price on the stock. Finally, Capital One Financial reissued an “overweight” rating on shares of Olema Pharmaceuticals in a research report on Thursday, February 22nd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Olema Pharmaceuticals has an average rating of “Buy” and an average target price of $21.43.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.